

Have You or
Someone You Know
Been Diagnosed with
Alzheimer's Disease?

**Consider Participating
in Athira's Clinical Trials**



About the Trials?

Athira's clinical trials of ATH-1017 are evaluating if a new investigational drug is safe and effective in improving symptoms of mild to moderate Alzheimer's disease. ATH-1017 is designed to boost a repair and regenerative pathway for brain cells, promoting brain health and function. ATH-1017 represents a new approach to treat Alzheimer's disease, targeting the root cause of memory decline by repairing the brain cells and rebuilding the brain networks.

The study drug is administered once daily via subcutaneous injection using a prefilled syringe (i.e. small injection under the skin that you can take at home; the injection is prepared and ready for administration).

- ◆ All necessary supplies to participate in the trial will be provided at no cost to you.
- ◆ You will receive all training necessary to perform the subcutaneous injection confidently.
- ◆ The overall treatment duration will last about 6 months.

A reliable caregiver or support person is required for study participation, to attend the clinical visits, answer questions from the study doctors, and help administer or supervise dosing of the study drug.


The clinical trials of ATH-1017 are evaluating if a new investigational drug is safe and effective in improving symptoms of mild to moderate Alzheimer's disease.

ATH-1017 is designed to boost a repair and regenerative pathway for brain cells, promoting brain health and function.

Who is Eligible?

You or someone you know may be eligible if you:

- ◆ Are between 55 and 85 years of age
- ◆ Have been diagnosed with Alzheimer's disease
- ◆ Have a reliable support person or caregiver who is willing to participate in study visits, report on daily activities and oversee or help you with taking ATH-1017



Participating in the Trials

Athira's clinical trials of ATH-1017 are seeking to enroll 300-400 participants with mild to moderate Alzheimer's disease in the United States and Australia.

Qualified participants will be randomly assigned to receive ATH-1017 or placebo. There are two dose levels of ATH-1017 for evaluation, so your chance of receiving active treatment vs. placebo is about 2:1. To maintain scientific and study integrity, neither participants nor clinical team will know the assignment of participants to the study group. Participation in the study is expected to last for about 8 months including 6 months of treatment duration.

What is Involved in the Trials?

Informed Consent

The study team will go over the detailed study information and criteria. You and your caregiver will be asked to sign consent forms before participating in the study.

Screening Visit

You and your caregiver will participate in a screening visit to determine your eligibility for study participation, including answering questions to evaluate your memory conditions and blood draws.

*The safety and efficacy of ATH-1017 for the treatment of mild to moderate Alzheimer's has not been previously established.

For more information, visit
www.athiraclinicaltrials.com



Study Group Randomization

If you meet the eligibility in the screening visit, you will return to the site for the next visit in 2 to 4 weeks. You will receive another memory test to confirm your eligibility before receiving the study drug, via a random assignment. There are two dose levels of ATH-1017 for evaluation so your chance of receiving active treatment vs. placebo is about 2:1.

Treatment Duration

The treatment duration will last 26-weeks (about 6 months). During this period, you or your caregiver will administer daily subcutaneous injections using the provided prefilled syringes.

- ◆ All necessary supplies to participate in the trial will be provided at no cost to you.
- ◆ You will receive all training necessary to perform the subcutaneous injection confidently.
- ◆ You and your caregiver will attend the clinical visits together. Like the screening visit, the study evaluation will include:
 - Answering questions to evaluate your memory conditions
 - Blood draws

Safety Follow-up

After you complete the treatment duration, you and your caregiver will be asked to return for a safety follow-up visit about 4 weeks after the last dose. The study evaluation will include answering questions to evaluate your memory conditions and blood draws.

Participation is Voluntary. Declining to Participate Will Not Have Any Detrimental Effects on Your Current Care.

- ◆ Study participation and study drug are free to all participants
- ◆ You may receive a stipend to compensate for time and effort for study participation including meals, travel, etc.

*The safety and efficacy of ATH-1017 for the treatment of mild to moderate Alzheimer's has not been previously established.

Talk to your doctor about participating in Athira's clinical trials of ATH-1017.

To learn more and
find a study location near you, please visit
www.athiraclinicaltrials.com

